Accumulating research has reported that EA alters ACh levels via modulation of its metabolism, including increasing the activities of cholinergic receptors, ACh, ChAT, and vesicular acetylcholine transporter (VAChT), and decreasing the activity of enzyme acetylcholinesterase (AChE), thus improving cognitive impairments (Lee et al., 2014; Han et al., 2018). Here, SLC18A3 is linked to Cognitive impairment.